The co-administration of rosiglitazone and PGC1α agonist significantly inhibited CRC proliferation, indicating that inhibiting glycolysis through the combined rosiglitazone and PGC1α agonist effectively inhibited CRC growth. This evidence concerns the gene PPARGC1A and colorectal carcinoma.